Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of 7-Ethyl-10-Hydroxycamptothecin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP1 known ✓ | P11387 | 17/20 | 0.76 |
| ▸ | MEN1 | O00255 | 3/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 3/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.71 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.71 |
| ▸ | CASP1 | P29466 | 1/20 | 0.71 |
| ▸ | CASP7 | P55210 | 1/20 | 0.71 |
| ▸ | HBB | P68871 | 1/20 | 0.71 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.71 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.68 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.68 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL34018 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29359781 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL29787648 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL16072280 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL13420265 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL733477 | 1.00 | MEN1 (1.00) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL27680702 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL28292269 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL1454961 | 0.99 | MEN1 (0.98) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 | |
| 7-Ethyl-10-Hydroxycamptothecin SCHEMBL30739326 | 0.95 | MEN1 (0.91) | MEN1KMT2ATOP1SMN1; SMN2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8049 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260144882-A1 | ANTI-NECTIN-4 ANTIBODY DRUG CONJUGATE AND USE THEREOF | BIO-THERA SOLUTIONS, LTD. (CN) | 2026-05-28 | — | — | US | claimed |
| CN-122094686-A | Oncolytic adenovirus and topoisomerase I inhibitors for the treatment of cancer | — | 2026-05-26 | — | — | CN | claimed |
| WO-2026103681-A1 | PROTEIN-GLYCAN CONJUGATE HAVING MULTIPLE PAYLOADS | 江苏康宁杰瑞生物制药有限公司 | 2026-05-21 | — | — | WO | claimed |
| WO-2026103680-A1 | BISPECIFIC ANTIBODY-MULTIPLE-PAYLOAD CONJUGATE | 江苏康宁杰瑞生物制药有限公司 | 2026-05-21 | — | — | WO | claimed |
| US-20260137700-A1 | PHARMACEUTICAL COMBINATION OF PRMT5 INHIBITOR AND DNA DAMAGE-INDUCING SUBSTANCE | SK BIOPHARMACEUTICALS CO LTD (KR) | 2026-05-21 | — | — | US | claimed |
| US-20260137796-A1 | PHARMACEUTICAL COMBINATIONS FOR SUBCUTANEOUS ADMINISTRATION AND USE THEREOF | SHANGHAI BAO PHARMACEUTICALS CO., LTD. (CN) | 2026-05-21 | — | — | US | claimed |
| EP-4743124-A1 | DE-N-ACETYLATED POLYSIALIC ACID (DPSA) BINDING AGENT, CONJUGATES, AND METHOD OF USING SAME | Saccharo, Inc. (US) | 2026-05-20 | — | — | EP | claimed |
| WO-2026098621-A1 | ENGINEERED ANTIBODY WITH SITE-SPECIFIC CONJUGATION, ANTIBODY-DRUG CONJUGATE, AND APPLICATION THEREOF | 百力司康生物医药(杭州)有限公司 | 2026-05-15 | — | — | WO | claimed |
| WO-2026098695-A1 | ANTIBODY LABELING METHOD | 上海睿智医药研究集团有限公司 | 2026-05-15 | — | — | WO | claimed |
| WO-2026101236-A1 | PEPTIDES SPECIFICALLY BINDING TO CCR8, AND USE THEREOF | 경희대학교 산학협력단 | 2026-05-15 | — | — | WO | claimed |
| EP-2900277-B1 | DOSAGES OF IMMUNOCONJUGATES OF ANTIBODIES AND SN-38 FOR IMPROVED EFFICACY AND DECREASED TOXICITY | IMMUNOMEDICS INC (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3954373-A1 | NEOADJUVANT USE OF ANTIBODY-DRUG CONJUGATES | Immunomedics, Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3953351-A1 | CONDENSED AZINES FOR EP300 OR CBP MODULATION AND INDICATIONS THEREFOR | Plexxikon Inc. (US) | 2022-02-16 | — | — | EP | claimed |
| EP-3952917-A1 | PROGRAMMABLE POLYMERIC DRUGS | Sony Group Corporation (JP) | 2022-02-16 | — | — | EP | claimed |
| CN-108992432-B | Nonwoven membrane for use as a drug delivery system | 加泰罗尼亚理工大学 | 2022-02-11 | — | — | CN | claimed |
| CN-114040779-A | Conjugates of cell binding molecules containing branched linkers and cytotoxic agents | 杭州多禧生物科技有限公司 | 2022-02-11 | — | — | CN | claimed |
| WO-2022031935-A1 | ANTIBODIES TARGETING EGFR AND USE THEREOF | DRAGONFLY THERAPEUTICS, INC. (US) | 2022-02-10 | — | — | WO | claimed |
| EP-3946419-A1 | METHODS OF TREATING CANCER WITH CHK1 INHIBITORS | Sierra Oncology, Inc. (US) | 2022-02-09 | — | — | EP | claimed |
| US-11242407-B2 | High-affinity anti-MERTK antibodies and uses thereof | INSPIRNA, INC. (US) | 2022-02-08 | — | — | US | claimed |
| WO-2022022649-A1 | DUAL-DRUG LINK ASSEMBLY UNIT AND DUAL-DRUG TARGETING LINKER-DRUG CONJUGATE | 成都科岭源医药技术有限公司 | 2022-02-03 | — | — | WO | claimed |